Esophageal carcinoma(EC)is a common malignant tumor of the upper digestive tract worldwide.An analysis of the latest data from cancer centers in China showed that the incidence of EC and the number of deaths due to EC...Esophageal carcinoma(EC)is a common malignant tumor of the upper digestive tract worldwide.An analysis of the latest data from cancer centers in China showed that the incidence of EC and the number of deaths due to EC in China in 2015 were 266,000 and 188,000,respectively,ranking sixth(6.3%)and fourth(8.0%)among all malignant tumors.The early diagnosis and treatment of EC and standardized diagnosis and treatment are important tasks for EC healthcare professionals in various centers across the country.At present,the 8th edition of the EC staging system jointly released by Union for International Cancer Control(UICC)and American Joint Committee on Cancer(AJCC)is the most recent,authoritative and widely used EC staging standard.The EC professional committee of the Chinese Anti-Cancer Association also organizes the"EC Standardization Campaign in China"every year to promote the development of EC diagnostic and treatment norms throughout the country.Since 2011,the EC Committee of the Chinese Anti-Cancer Association has published the Guidelines for Standardized Diagnosis and Treatment of EC.Considering the increasing number of EC clinical studies and the continuous progress in diagnostic and treatment technologies in recent years,the updated Guidelines will include the latest progress in the diagnosis and treatment of EC,with a goal of promoting the forward development of EC diagnosis and treatment in clinical practice.展开更多
Purpose To analyze the long-term overall survival(OS)and influencing factors of patients with esophageal squamous cell cancer(ESCC)under surgical treatment.Method We collected patients with ESCC who received surgical ...Purpose To analyze the long-term overall survival(OS)and influencing factors of patients with esophageal squamous cell cancer(ESCC)under surgical treatment.Method We collected patients with ESCC who received surgical treatment in Sichuan Cancer Hospital&institute from January 2010 to December 2017,and selected 2,766 patients with thoracic esophageal carcinoma with relatively complete follow-up results as the objects of this study.We analyzed the characteristics,postoperative complications and long-term OS results of those patients.Results Of the 2766 patients,81.6%were male,midthoracic esophageal cancer accounted for 53.5%.McKeown was used in 72.0%of patients and Ivor-Lewis was used in 26.4%of patients.About 47.8%of patients received minimally invasive esophagectomy(MIE).The overall complication rate was 25.8%.The 1-year,3-year and 5-year OS rates were 86.2%,57.5%and 46.8%,respectively.McKeown had a better long-term OS rate than Ivor-Lewis(49.5%vs 41.2%,P<0.001),and MIE is superior to open surgery(51.8%vs 42.5%,P<0.001).Conclusion McKeown has advantages over Ivor-Lewis.MIE results in better long-term survival outcomes for patients.But more prospective randomized controlled trials with large samples are needed.展开更多
基金supported by China Anti-Cancer Association(CACA).
文摘Esophageal carcinoma(EC)is a common malignant tumor of the upper digestive tract worldwide.An analysis of the latest data from cancer centers in China showed that the incidence of EC and the number of deaths due to EC in China in 2015 were 266,000 and 188,000,respectively,ranking sixth(6.3%)and fourth(8.0%)among all malignant tumors.The early diagnosis and treatment of EC and standardized diagnosis and treatment are important tasks for EC healthcare professionals in various centers across the country.At present,the 8th edition of the EC staging system jointly released by Union for International Cancer Control(UICC)and American Joint Committee on Cancer(AJCC)is the most recent,authoritative and widely used EC staging standard.The EC professional committee of the Chinese Anti-Cancer Association also organizes the"EC Standardization Campaign in China"every year to promote the development of EC diagnostic and treatment norms throughout the country.Since 2011,the EC Committee of the Chinese Anti-Cancer Association has published the Guidelines for Standardized Diagnosis and Treatment of EC.Considering the increasing number of EC clinical studies and the continuous progress in diagnostic and treatment technologies in recent years,the updated Guidelines will include the latest progress in the diagnosis and treatment of EC,with a goal of promoting the forward development of EC diagnosis and treatment in clinical practice.
基金supported by grants from the National Key Research and Development Program(2022YFC2403400)International Cooperation Projects of Science and Technology Department of Sichuan Province(Grant No.2020YFH0169)+2 种基金the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province(Grant No.2023YFS0044,2023YFQ0055,2023YFQ0056,No.2021YJ0118)the Wu Jieping Clinical Research Projects(Grant No.320.6750.2020-15-3)Sichuan Province Clinical Key Specialty Construction Project。
文摘Purpose To analyze the long-term overall survival(OS)and influencing factors of patients with esophageal squamous cell cancer(ESCC)under surgical treatment.Method We collected patients with ESCC who received surgical treatment in Sichuan Cancer Hospital&institute from January 2010 to December 2017,and selected 2,766 patients with thoracic esophageal carcinoma with relatively complete follow-up results as the objects of this study.We analyzed the characteristics,postoperative complications and long-term OS results of those patients.Results Of the 2766 patients,81.6%were male,midthoracic esophageal cancer accounted for 53.5%.McKeown was used in 72.0%of patients and Ivor-Lewis was used in 26.4%of patients.About 47.8%of patients received minimally invasive esophagectomy(MIE).The overall complication rate was 25.8%.The 1-year,3-year and 5-year OS rates were 86.2%,57.5%and 46.8%,respectively.McKeown had a better long-term OS rate than Ivor-Lewis(49.5%vs 41.2%,P<0.001),and MIE is superior to open surgery(51.8%vs 42.5%,P<0.001).Conclusion McKeown has advantages over Ivor-Lewis.MIE results in better long-term survival outcomes for patients.But more prospective randomized controlled trials with large samples are needed.
